

REMARKS

The foregoing amendments are presented to place the application in compliance with the Sequence Rules under 37 C.F.R. § 1.821-1.825.

Enclosed herewith is a revised substitute Sequence Listing in both paper and computer readable form as required by 37 C.F.R. § 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.


The substitute Sequence Listing corrects the errors noted in the Notice to Comply. A copy of the Notice is attached herewith as required. In particular, the Sequence Listing and the specification have been revised to include corresponding SEQ ID Nos. for the amino acid sequences disclosed in Fig. 4. The substitute Sequence Listing has been run through the PTO Checker software (version 4.4.0) and no errors were found.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the Sequence Rules under 37 C.F.R. § 1.821-1.825.

Favorable action on the merits is respectfully requested.

Respectfully submitted,

Seishi KATO et al.

By: 
Jay F. Williams
Registration No. 48,036
Attorney for Applicants

JFW/akl
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 26, 2006

ATTACHMENTS

1. Copy of the Notification to Comply with Requirements for Patent Applications
Containing Nucleotide and/or Amino Acid Sequence Disclosures; and
2. Revised substitute Sequence Listing (paper and CRF).